Search Results

You are looking at 71 - 80 of 478 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, and Qian Zhang

.11) Figure 1 . Paobinostat had a significantly lower risk of lymphopenia (OR 0.25 95% CI 0.15-0.42, p=<0.0001) Panobinostat was however, associated with two times more risk of anemia (OR 2.82 95% CI 1.82-4.38, p=<0.0001), fatigue (OR 2.36 95% CI 1.64-3.38, p

Full access

Daniel Shasha, Pierre Cremieux, and Louis Harrison

patients undergoing radiation therapy . Semin Oncol 2001 ; 28 ( suppl 8 ): 54 – 59 . 4 Irvine D Vincent L Graydon JE . The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: A comparison

Full access

Mustafa Özgüroğlu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Xuanyao He, Jennifer McGinniss, Giuseppe Gullo, Petra Rietschel, and Ruben GW Quek

statistically significant favorable difference in overall change from baseline in role functioning (8.59; 95% CI, 0.16, 17.01; p=0.0459), emotional functioning (7.27; 95% CI, 1.86, 12.69; p=0.0095), and symptoms of fatigue (-8.19; 95% CI, -15.40, -0.98; p=0

Full access

Sri Harsha Tella, Jaclynn Wessling, Foster Nathan, Shi Qian, Tran Nguyen, Robert McWillimas, Alberts Steven, Minetta Liu, Mitesh Borad, Wen Wee Ma, Mindy Hartgers, Leslie Washburn, Fruth Briant, Martin Fernandezzapico, Tara L Hogenson, Henry Pitot, Zhaohui Jin, and Amit Mahipal

(11%), fatigue (7%), and diarrhea (7%). 9 out of 27 (33%) and 14/27 (52%) had dose reductions secondary to AEs (cytopenias and fatigue) for trifluridine/tipiracil and irinotecan, respectively and 1 patient discontinued the therapy due to adverse events

Full access

Alexandra Hunt, Elizabeth Handorf, Vipin Khare, Matthew Blau, Yana Chertock, Carolyn Fang, Michael J. Hall, and Rishi Jain

evaluate the frequency of specific stressors including: practical (e.g. insurance/financial), family (e.g. family health issues), emotional (e.g. nervousness), or physical (e.g. fatigue). Adverse events on trial including hospitalizations, toxicities, or

Full access

Karen Wonders, Rob Wise, and Danielle Ondreka

strength, quality of life, depression, fear fatigue, and pain all improved following the exercise intervention. Conclusion: Exercise is an effective means to manage treatment-related symptoms in cancer and should be a part of the standard of care.

Full access

Murali Sundaram, Kathleen L. Deering, Dolly Sharma, Qing Harshaw, Jeremiah Trudeau, and Jacqueline C. Barrientos

. Respondents completed demographic/clinical information and surveys via phone (Functional Assessment of Cancer Therapy-General [FACT-G], FACT-Leukemia, and Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue and Cancer Therapy Satisfaction

Full access

Karen Hock and Cari Utendorf

fibrosis and fatigue. Results: The data will demonstrate an increase in percentage of pre-operative assessments since the implementation of this program in January 2018. In addition, the data will demonstrate the increased opportunity to treat subclinical

Full access

Ping Jiang, Ang Qu, Weijuan Jiang, Xiuwen Deng, and Junjie Wang

twice a week. Dose escalation followed a 3 + 3 design. The DLT was defined as grade 3 or 4 nonhematologic toxicity, excluding nausea, vomiting and alopecia, decreased appetite and fatigue, or grade 4 hematologic toxicity. Results : This study was

Full access

John Mascarenhas, Arianna Kee, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Richard Perry, and Ali McBride

consensus statements suggest patient-reported symptoms of fatigue, poor concentration, inactivity, and bone pain were too general to define RUX failure compared with other specific MF symptoms ie, night sweats. Following RUX failure, consensus